Gastroenterology
Volume 129, Issue 3 , Pages 819-826, September 2005

Increased Risk for Demyelinating Diseases in Patients With Inflammatory Bowel Disease

  • Gauree Gupta

      Affiliations

    • Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
  • ,
  • Joel M. Gelfand

      Affiliations

    • Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    • Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
  • ,
  • James D. Lewis

      Affiliations

    • Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    • Department of Internal Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    • Corresponding Author InformationAddress requests for reprints to: James D. Lewis, MD, MSCE, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, 720 Blockley Hall, 423 Guardian Drive, Philadelphia, Pennsylvania 19104-6021. fax: (215) 573-0813.

Received 27 January 2005; accepted 26 May 2005.

Background & Aims: Reports of multiple sclerosis (MS), demyelination, and optic neuritis (ON) associated with anti–tumor necrosis factor α therapy resulted in warnings on prescribing instructions for infliximab, etanercept, and adalimumab. However, the underlying relationship between IBD and these neurologic conditions has not been established. Methods: We performed a retrospective cohort study and a retrospective cross-sectional study using 1988 to 1997 data from the General Practice Research Database. A total of 7988 Crohn’s disease and 12,185 ulcerative colitis patients were matched for age, sex, and primary care practice to 80,666 randomly selected controls. In the cohort study, incident cases of MS, demyelination, and/or ON (MS/D/ON) had to occur at least 1 year after registration with the physician and after the diagnosis of IBD. In the cross-sectional study, the diagnosis of MS/D/ON could either precede or follow the IBD diagnosis. Results: In the cohort study, the incidence of MS/D/ON was higher in patients with Crohn’s disease and ulcerative colitis compared with their matched controls, reaching statistical significance for ulcerative colitis (ulcerative colitis incidence rate ratio [IRR], 2.63; 95% confidence interval, 1.29–5.15; Crohn’s disease IRR, 2.12; 95% confidence interval, .94–4.50). In the cross-sectional study, MS/D/ON was more prevalent in patients with Crohn’s disease and ulcerative colitis compared with their matched controls (Crohn’s disease odds ratio, 1.54; 95% confidence interval, 1.03–2.32; ulcerative colitis odds ratio, 1.75; 95% confidence interval, 1.28–2.39). Conclusions: Demyelinating diseases occur more commonly among patients with IBD than among non-IBD patients. Future studies should clarify whether treatment with tumor necrosis factor α blockers results in further increased incidence of MS/D/ON among IBD patients.

Abbreviations used in this paper:  AZA/6-MP, azathioprine or 6-mercaptopurine , CI, confidence interval , GPRD, General Practice Research Database , MS, multiple sclerosis , MS/D/ON, multiple sclerosis, demyelination, and/or optic neuritis , ON, optic neuritis , TNFα, tumor necrosis factor α

 

 Supported by grant 5-T35-DK060441-03. J.M.G. has received research support and consulting honorarium from Amgen. J.D.L. has received consulting honorarium and research support from Wyeth during the past 2 years for work unrelated to anti–tumor necrosis factor α therapies and is a co-investigator of research funded by Johnson and Johnson but does not receive any direct compensation as part of the research.

PII: S0016-5085(05)01124-8

doi:10.1053/j.gastro.2005.06.022

Refers to article:

  • Inflammatory Bowel Disease Extending Its Reach

    Edward V. Loftus
    Gastroenterology September 2005 (Vol. 129, Issue 3, Pages 1117-1120)

Gastroenterology
Volume 129, Issue 3 , Pages 819-826, September 2005